[go: up one dir, main page]

SG11202011097YA - Bioreactor for rna in vitro transcription - Google Patents

Bioreactor for rna in vitro transcription

Info

Publication number
SG11202011097YA
SG11202011097YA SG11202011097YA SG11202011097YA SG11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA
Authority
SG
Singapore
Prior art keywords
bioreactor
rna
vitro transcription
transcription
vitro
Prior art date
Application number
SG11202011097YA
Inventor
Panah Benyamin Yazdan
Tilmann Roos
Martin Kunze
Felix Bertsch
Aniela Wochner
Michael Rauen
Philipp Hoffmann
Original Assignee
Curevac Ag
Tesla Grohmann Automation Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag, Tesla Grohmann Automation Gmbh filed Critical Curevac Ag
Publication of SG11202011097YA publication Critical patent/SG11202011097YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6865Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00Other mixers; Mixing plants; Combinations of mixers
    • B01F33/45Magnetic mixers; Mixers with magnetically driven stirrers
    • B01F33/451Magnetic mixers; Mixers with magnetically driven stirrers wherein the mixture is directly exposed to an electromagnetic field without use of a stirrer, e.g. for material comprising ferromagnetic particles or for molten metal
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00Other mixers; Mixing plants; Combinations of mixers
    • B01F33/45Magnetic mixers; Mixers with magnetically driven stirrers
    • B01F33/452Magnetic mixers; Mixers with magnetically driven stirrers using independent floating stirring elements
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/50Mixing receptacles
    • B01F35/53Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components
    • B01F35/531Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components with baffles, plates or bars on the wall or the bottom
    • B01F35/5312Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components with baffles, plates or bars on the wall or the bottom with vertical baffles mounted on the walls
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90Heating or cooling systems
    • B01F35/92Heating or cooling systems for heating the outside of the receptacle, e.g. heated jackets or burners
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00Bioreactors or fermenters specially adapted for specific uses
    • C12M21/18Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/02Stirrer or mobile mixing elements
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48Automatic or computerized control
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/1013Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90Heating or cooling systems
    • B01F2035/98Cooling
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90Heating or cooling systems
    • B01F2035/99Heating
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22Mixing of ingredients for pharmaceutical or medical compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00Reaction characterised by the enzymatic activity
    • C12Q2521/10Nucleotidyl transfering
    • C12Q2521/119RNA polymerase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/143Magnetism, e.g. magnetic label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Sustainable Development (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Hardware Design (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
SG11202011097YA 2018-06-28 2019-06-28 Bioreactor for rna in vitro transcription SG11202011097YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018067504 2018-06-28
PCT/EP2019/067323 WO2020002598A1 (en) 2018-06-28 2019-06-28 Bioreactor for rna in vitro transcription

Publications (1)

Publication Number Publication Date
SG11202011097YA true SG11202011097YA (en) 2020-12-30

Family

ID=62837899

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011097YA SG11202011097YA (en) 2018-06-28 2019-06-28 Bioreactor for rna in vitro transcription

Country Status (13)

Country Link
US (2) US12371646B2 (en)
EP (2) EP3814495B1 (en)
JP (1) JP7352581B2 (en)
KR (1) KR20210027368A (en)
CN (1) CN112334579B (en)
AU (1) AU2019293714C1 (en)
BR (1) BR112020025601A8 (en)
CA (1) CA3102135A1 (en)
IL (1) IL279759B2 (en)
MX (1) MX2020013148A (en)
RU (1) RU2765877C1 (en)
SG (1) SG11202011097YA (en)
WO (1) WO2020002598A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
MX362981B (en) 2012-03-27 2019-02-28 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression.
CN105517569A (en) 2013-08-21 2016-04-20 库瑞瓦格股份公司 Rabies vaccine
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CN105473157A (en) 2013-08-21 2016-04-06 库瑞瓦格股份公司 Combination vaccine
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
ES2754239T3 (en) 2014-03-12 2020-04-16 Curevac Ag Combination of vaccination and OX40 agonists
DE202015009961U1 (en) 2014-12-12 2022-01-25 Curevac Ag Artificial nucleic acid molecules for improved protein expression
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
ES2960429T3 (en) 2015-05-29 2024-03-04 Curevac Mfg Gmbh Method for producing and purifying RNA, comprising at least one tangential flow filtration step
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
US12297489B2 (en) 2017-05-17 2025-05-13 CureVac Manufacturing GmbH Method for determining at least one quality parameter of an RNA sample
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
RU2020117848A (en) 2017-11-08 2021-12-08 Куревак Аг PHK SEQUENCE ADAPTATION
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
SG11202005760PA (en) 2017-12-21 2020-07-29 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
WO2019202035A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
SG11202011097YA (en) 2018-06-28 2020-12-30 Curevac Ag Bioreactor for rna in vitro transcription
US11421226B2 (en) * 2018-10-17 2022-08-23 Ramot At Tel-Aviv University Ltd. Programmable artificial cell
TW202039534A (en) 2018-12-14 2020-11-01 美商美國禮來大藥廠 Kras variant mrna molecules
SG11202106666UA (en) 2018-12-21 2021-07-29 Curevac Ag Methods for rna analysis
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
AU2021216658A1 (en) 2020-02-04 2022-06-23 CureVac SE Coronavirus vaccine
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN115667509A (en) * 2020-05-01 2023-01-31 螺旋纳米技术公司 Compositions and methods for RNA synthesis
EP4150105A1 (en) * 2020-05-12 2023-03-22 Makatsoris, Charalampos A method and modular apparatus for the synthesis of rna-based therapeutics
GB2597436B (en) * 2020-05-12 2025-03-26 Makatsoris Charalampos A method and apparatus for RNA synthesis
BR112022024248A2 (en) 2020-05-29 2023-10-10 CureVac SE NUCLEIC ACID-BASED COMBINATION VACCINES
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
US20240246056A1 (en) 2020-09-01 2024-07-25 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
US12458604B2 (en) 2020-10-14 2025-11-04 The Trustees Of The University Of Pennsylvania Methods of lipid nanoparticle manufacture and compositions derived therefrom
GB2617472B (en) * 2020-10-23 2025-08-06 Linearx Inc Compositions and methods for RNA synthesis
WO2022112498A1 (en) 2020-11-27 2022-06-02 CureVac RNA Printer GmbH A device for preparing a dna product by means of capillary polymerase chain reaction
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
US20240150719A1 (en) * 2021-02-22 2024-05-09 The Board Of Regents Of The University Of Texas System Magnetic shear bioreactor apparatus and methods
MX2023011400A (en) 2021-03-26 2023-10-09 Glaxosmithkline Biologicals Sa Immunogenic compositions.
EP4351777A4 (en) * 2021-06-07 2025-04-16 The University of Massachusetts Apparatus and method for continuous production of rna
BE1030468B1 (en) 2022-04-20 2023-11-21 Quantoom Biosciences S A SYSTEM AND METHOD FOR RNA PRODUCTION
CN119234155A (en) 2022-04-15 2024-12-31 广通生物科学公司 System and method for producing RNA
CN114540444B (en) * 2022-04-23 2022-08-09 江苏申基生物科技有限公司 Capping composition, preparation method thereof and in-vitro transcription reaction system
CN115106356B (en) * 2022-07-06 2023-06-06 眉山市城投中恒能环保科技有限公司 Treatment method and treatment system for kitchen waste recovery
AU2023353931A1 (en) 2022-09-26 2025-03-20 Glaxosmithkline Biologicals Sa Influenza virus vaccines
EP4344769B1 (en) * 2022-09-30 2025-03-19 Technische Universität Clausthal System for continuous manufacture of biomolecules
DE202023106198U1 (en) 2022-10-28 2024-03-21 CureVac SE Nucleic acid-based vaccine
CN116180478A (en) * 2023-02-28 2023-05-30 江苏理文造纸有限公司 Utilize straw automation papermaking device
CN222476570U (en) 2023-03-17 2025-02-14 广通生物科学公司 System and treatment vessel for treating biochemical products by means of magnetic particles
WO2024209418A1 (en) * 2023-04-07 2024-10-10 BioNTech SE Heating and cooling jacket for fluid vessels
WO2024235451A1 (en) 2023-05-16 2024-11-21 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
WO2025022178A2 (en) * 2023-07-24 2025-01-30 Apte Zachary Schulz In-situ mrna vaccine production method and device
WO2025040263A1 (en) 2023-08-24 2025-02-27 CureVac Manufacturing GmbH Purification process for in vitro amplified dna
KR20250047212A (en) * 2023-09-27 2025-04-03 포항공과대학교 산학협력단 Microfluid reaction device and mRNA synthesis method using the same
CN119709730A (en) * 2023-09-28 2025-03-28 康码(上海)生物科技有限公司 A DNA microsphere and its preparation method and application
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
GB202406294D0 (en) 2024-05-06 2024-06-19 Thermo Fisher Scientific Baltics Uab Methods and compositions for producing capped mRNA
EP4660288A1 (en) 2024-06-07 2025-12-10 Sartorius Stedim Biotech GmbH Bioreactor, bioreactor vessel and closure component for a bioreactor vessel
EP4660291A1 (en) 2024-06-07 2025-12-10 Sartorius Stedim Biotech GmbH Bioreactor and bioreactor vessel
WO2026003316A1 (en) * 2024-06-28 2026-01-02 BioNTech SE Method for pcr
CN120115054B (en) * 2025-05-08 2025-08-05 南京航空航天大学 A powder mixing method for a lunar base sandwich shell and a sandwich shell structure

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898565A (en) * 1954-07-02 1959-08-04 Mc Graw Edison Co Magnetic core
SE460706B (en) * 1987-12-30 1989-11-13 Stefan Loefgren OMROERNINGSORGAN
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US6955793B1 (en) * 1997-06-18 2005-10-18 Arencibia Jr Jose P Temperature controlled reaction vessel
US6361749B1 (en) * 1998-08-18 2002-03-26 Immunivest Corporation Apparatus and methods for magnetic separation
WO2000062034A2 (en) * 1999-04-09 2000-10-19 Shot, Inc. Multistage electromagnetic separator for purifying cells, chemicals and protein structures
ES2340499T3 (en) 2001-06-05 2010-06-04 Curevac Gmbh TUMOR ANTIGEN ARNM STABILIZED WITH AN INCREASED G / C CONTENT.
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
WO2004015062A2 (en) * 2002-08-12 2004-02-19 New England Biolabs, Inc. Methods and compositions relating to gene silencing
DE10335833A1 (en) 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
DE102004042546A1 (en) 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
DE102005023170A1 (en) 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
FI20051248L (en) 2005-12-02 2007-06-03 Bio Nobile Oy Enrichment unit and enrichment method for biological components
DE102006035618A1 (en) 2006-07-31 2008-02-07 Curevac Gmbh Nucleic acid of the formula (I): GlXmGn, in particular as immunostimulating adjuvant
DE102006061015A1 (en) 2006-12-22 2008-06-26 Curevac Gmbh Process for the purification of RNA on a preparative scale by HPLC
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
GB0724404D0 (en) 2007-05-29 2008-01-30 Invitrogen Dynal As A sample vessel retaining portion
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
KR101483715B1 (en) 2008-01-31 2015-01-19 큐어백 게엠바하 NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS/ADJUVANTS
EP2306959A2 (en) * 2008-07-11 2011-04-13 The General Hospital Corporation Magnetic apparatus for blood separation
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9157891B2 (en) * 2008-10-16 2015-10-13 Koninklijke Philips N.V. Biosensor with quadrupole magnetic actuation system
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
GB2481425A (en) * 2010-06-23 2011-12-28 Iti Scotland Ltd Method and device for assembling polynucleic acid sequences
ES2558106T3 (en) 2010-07-30 2016-02-02 Curevac Ag Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
KR101870311B1 (en) * 2012-03-09 2018-06-25 (주)바이오니아 Compositions for hot start reverse transcription reaction or hot start reverse transcription polymerase chain reaction
MX362981B (en) 2012-03-27 2019-02-28 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression.
CA2866955A1 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
ES2660129T3 (en) 2012-03-27 2018-03-20 Curevac Ag Artificial nucleic acid molecules comprising a 5'UTR-TOP
GB201208547D0 (en) * 2012-05-15 2012-06-27 Life Technologies As Sample holder
EP3498267A1 (en) 2012-05-25 2019-06-19 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
MX385338B (en) 2013-02-22 2025-03-18 CureVac SE Combination of vaccination and inhibition of the pd-1 pathway
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
PT2970948T (en) * 2013-03-15 2019-03-20 Glaxosmithkline Biologicals Sa RNA Purification Methods
SG11201510748PA (en) 2013-08-21 2016-03-30 Curevac Ag Composition and vaccine for treating lung cancer
CN105473157A (en) 2013-08-21 2016-04-06 库瑞瓦格股份公司 Combination vaccine
CN105517569A (en) 2013-08-21 2016-04-20 库瑞瓦格股份公司 Rabies vaccine
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
AU2014310930A1 (en) 2013-08-21 2016-01-21 Curevac Ag Composition and vaccine for treating prostate cancer
CN105451779A (en) 2013-08-21 2016-03-30 库瑞瓦格股份公司 Method for increasing expression of RNA-encoded proteins
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
AU2014375404C1 (en) 2013-12-30 2020-11-19 CureVac Manufacturing GmbH Methods for RNA analysis
KR102399799B1 (en) 2013-12-30 2022-05-18 큐어백 아게 Artificial nucleic acid molecules
ES2754239T3 (en) 2014-03-12 2020-04-16 Curevac Ag Combination of vaccination and OX40 agonists
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
MX382298B (en) * 2014-06-10 2025-03-12 Curevac Mfg Gmbh METHODS AND MEANS FOR INCREASING RNA PRODUCTION.
ES2711852T3 (en) * 2014-08-12 2019-05-07 Abb Schweiz Ag Magnet that presents regions of different magnetic properties and procedure to form said magnet
WO2016062788A1 (en) * 2014-10-24 2016-04-28 Ait Austrian Institute Of Technology Gmbh Microfluidic chip for biological analysis
DE202015009961U1 (en) 2014-12-12 2022-01-25 Curevac Ag Artificial nucleic acid molecules for improved protein expression
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
CA2966092A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
EP4353257A3 (en) 2015-04-13 2024-08-07 CureVac Manufacturing GmbH Method for producing rna compositions
CN107567497A (en) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Lyophilization of RNA
US10293058B2 (en) 2015-04-22 2019-05-21 Curevac Ag RNA containing composition for treatment of tumor diseases
SG11201708681SA (en) 2015-04-30 2017-11-29 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
EP3289101B1 (en) 2015-04-30 2021-06-23 CureVac AG Immobilized poly(n)polymerase
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
KR20180004820A (en) 2015-05-15 2018-01-12 큐어백 아게 A novel prime-boost therapy comprising administration of at least one mRNA construct
EP3916091A3 (en) 2015-05-20 2022-03-30 CureVac AG Dry powder composition comprising long-chain rna
WO2016184576A2 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
ES2960429T3 (en) 2015-05-29 2024-03-04 Curevac Mfg Gmbh Method for producing and purifying RNA, comprising at least one tangential flow filtration step
EP3303575B1 (en) 2015-05-29 2022-03-16 CureVac AG Method for adding cap structures to rna using immobilized enzymes
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
EP4239080A3 (en) 2015-07-01 2023-11-01 CureVac Manufacturing GmbH Method for analysis of an rna molecule
US10501768B2 (en) 2015-07-13 2019-12-10 Curevac Ag Method of producing RNA from circular DNA and corresponding template DNA
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
WO2017025120A1 (en) 2015-08-07 2017-02-16 Curevac Ag Process for the in vivo production of rna in a host cell
EP3825407A1 (en) 2015-08-10 2021-05-26 CureVac Real Estate GmbH Method of increasing the replication of a circular dna molecule
AU2016316439B2 (en) 2015-08-28 2022-02-24 CureVac SE Artificial nucleic acid molecules
LT4104687T (en) 2015-09-21 2024-02-26 Trilink Biotechnologies, Llc Compositions and methods for synthesizing 5 -capped rnas
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
US20180312545A1 (en) 2015-11-09 2018-11-01 Curevac Ag Optimized nucleic acid molecules
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
JP2017085951A (en) 2015-11-09 2017-05-25 株式会社リコー Jig, processing apparatus, processing method, and cDNA synthesis method
WO2017090134A1 (en) 2015-11-25 2017-06-01 神栄テクノロジー株式会社 Particle sensor
WO2017108087A1 (en) 2015-12-21 2017-06-29 Curevac Ag Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017137095A1 (en) 2016-02-12 2017-08-17 Curevac Ag Method for analyzing rna
EP3417069A1 (en) 2016-02-15 2018-12-26 CureVac AG Method for analyzing by-products of rna in vitro transcription
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3433361A1 (en) 2016-03-24 2019-01-30 CureVac AG Immobilized inorganic pyrophosphatase (ppase)
US20190343942A1 (en) 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4477662A3 (en) 2016-05-04 2025-03-19 CureVac SE Nucleic acid molecules and uses thereof
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
EP3464619A1 (en) 2016-05-25 2019-04-10 CureVac AG Novel biomarkers
US11478552B2 (en) 2016-06-09 2022-10-25 Curevac Ag Hybrid carriers for nucleic acid cargo
EP3468609A1 (en) 2016-06-09 2019-04-17 CureVac AG Cationic carriers for nucleic acid delivery
WO2017212008A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
US20190336611A1 (en) 2016-06-09 2019-11-07 Curevac Ag Hybrid carriers for nucleic acid cargo
BR112019000598A2 (en) 2016-08-19 2019-07-02 Curevac Ag rna for cancer therapy
WO2018041921A1 (en) 2016-08-31 2018-03-08 Curevac Ag Mixing device for the production of a liquid nucleic acid composition
JP2018057333A (en) 2016-10-06 2018-04-12 株式会社リコー TREATMENT KIT, TREATMENT METHOD, cDNA SYNTHESIS METHOD AND TREATMENT DEVICE
WO2018075827A1 (en) 2016-10-19 2018-04-26 Arcturus Therapeutics, Inc. Trinucleotide mrna cap analogs
KR20190093816A (en) 2016-10-26 2019-08-26 큐어백 아게 Lipid nanoparticle mRNA vaccine
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
US11464836B2 (en) 2016-12-08 2022-10-11 Curevac Ag RNA for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3595715A1 (en) 2017-03-17 2020-01-22 CureVac AG Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
CN106916743B (en) 2017-03-19 2019-02-12 北京化工大学 Integrated nucleic acid extraction and amplification detection system
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
US12297489B2 (en) 2017-05-17 2025-05-13 CureVac Manufacturing GmbH Method for determining at least one quality parameter of an RNA sample
EP3424524B1 (en) 2017-07-04 2024-12-11 CureVac SE Cancer rna-vaccine
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag Bunyavirales vaccine
MX2020003995A (en) 2017-10-19 2020-07-22 Curevac Ag NEW ARTIFICIAL NUCLEIC ACID MOLECULES.
RU2020117848A (en) 2017-11-08 2021-12-08 Куревак Аг PHK SEQUENCE ADAPTATION
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
SG11202005760PA (en) 2017-12-21 2020-07-29 Curevac Ag Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
EP3773702A2 (en) 2018-04-05 2021-02-17 CureVac AG Novel yellow fever nucleic acid molecules for vaccination
WO2019202035A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
SG11202011097YA (en) 2018-06-28 2020-12-30 Curevac Ag Bioreactor for rna in vitro transcription
TW202039534A (en) 2018-12-14 2020-11-01 美商美國禮來大藥廠 Kras variant mrna molecules
SG11202106666UA (en) 2018-12-21 2021-07-29 Curevac Ag Methods for rna analysis
US20220040281A1 (en) 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
EP4491229A3 (en) 2019-02-08 2025-05-14 CureVac SE Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
EP3986452A1 (en) 2019-06-18 2022-04-27 CureVac AG Rotavirus mrna vaccine
KR20220047319A (en) 2019-08-14 2022-04-15 큐어백 아게 RNA Combinations and Compositions with Reduced Immunostimulatory Properties
EP4076647A1 (en) 2019-12-20 2022-10-26 CureVac AG Lipid nanoparticles for delivery of nucleic acids
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
BR112022024248A2 (en) 2020-05-29 2023-10-10 CureVac SE NUCLEIC ACID-BASED COMBINATION VACCINES
EP4165205A1 (en) 2020-06-15 2023-04-19 CureVac SE Analysis of nucleic acid mixtures

Also Published As

Publication number Publication date
JP2021528051A (en) 2021-10-21
EP4273266A3 (en) 2024-03-13
IL279759A (en) 2021-03-01
US20250313788A1 (en) 2025-10-09
AU2019293714B2 (en) 2023-03-30
EP3814495A1 (en) 2021-05-05
WO2020002598A1 (en) 2020-01-02
CN112334579A (en) 2021-02-05
RU2765877C1 (en) 2022-02-04
BR112020025601A8 (en) 2022-07-05
IL279759B2 (en) 2026-02-01
JP7352581B2 (en) 2023-09-28
US20210261897A1 (en) 2021-08-26
EP3814495B1 (en) 2023-06-07
EP3814495C0 (en) 2023-06-07
CA3102135A1 (en) 2020-01-02
EP4273266A2 (en) 2023-11-08
KR20210027368A (en) 2021-03-10
MX2020013148A (en) 2021-03-02
US12371646B2 (en) 2025-07-29
CN112334579B (en) 2026-01-16
AU2019293714A1 (en) 2020-11-12
IL279759B1 (en) 2025-10-01
AU2019293714C1 (en) 2023-09-21
BR112020025601A2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
IL279759B2 (en) Bioreactor for rna in vitro transcription
SG11201708681SA (en) Method for in vitro transcription using an immobilized restriction enzyme
EP3938507A4 (en) Fed-batch in vitro transcription process
EP3728596A4 (en) Nucleic acid construct for in vitro and in vivo gene expression
SG11202011539VA (en) Modified guide rnas for gene editing
EP3504315A4 (en) Bioreactor
ZA201902420B (en) Method for amplifying antigen-specific regulatory t cells in vitro
PT3294903T (en) Method for in vitro diagnosis of dementia with lewy bodies using alphasynuclein gene transcripts
EP3749335A4 (en) Perfusion enabled bioreactors
GB201913196D0 (en) Culture method
EP3717631C0 (en) Cell culture methods
IL314599A (en) Cell culture methods
EP3164495A4 (en) Microorganisms for producing 4c-5c compounds with unsaturation and methods related thereto
EP3368537A4 (en) Process for preparing ibrutinib and its intermediates
GB201909144D0 (en) Culture medium
IL262125A (en) Selective bioreactor for microalgae
GB201814532D0 (en) in vitro dianostic assay methods
PL3630946T3 (en) Cell culture methods
EP3069591A4 (en) Bioreactor for in vitro plant culture
EP3389363B8 (en) A process for in vitro
SG11202111135PA (en) Cell culture media comprising keto acids
EP3681365A4 (en) Large-scale bioreactor
PT3841214T (en) Charcoal-free culture media for legionella
LT3234100T (en) Bioreactor and fermentation process for producing hydrogen
PL3647404T3 (en) Bioreactor